View the official press release distributed through PR Newswire.
The Revolution CTC Enrichment Kit (Epithelial Cell Origin)™ is nRichDX's latest product to advance liquid biopsy development.
IRVINE, Calif., September 29, 2023 – nRichDX® has launched its new RUO-labeled CTC enrichment kit that uniquely isolates Circulating Tumor Cells (CTCs) from up to 40 mL of whole blood samples to help researchers advance liquid biopsy assay research and development.
Circulating Tumor Cells (CTCs) are a class of analytes frequently used in liquid biopsy assays and may signal more aggressive cancers in metastasis, or spreading to other parts of the body.
A New CTC Enrichment Application for the Revolution Platform
Designed to expand the range of analytes available from a liquid biopsy sample.
RUO-labeled enrichment of circulating tumor cells from up to 40 mL of whole blood
Targets CTCs originating from epithelial tissues
Uses immunomagnetic enrichment with established cellular markers including EpCAM
Designed to work alongside other Revolution Kits on the Revolution Sample Prep System
Targeting Circulating Tumor Cells from Carcinomas
The new kit captures CTCs from cancers originating in epithelial cells, known as carcinomas.
Carcinomas include leading cancer types such as cancers of the breast, lung, colon, prostate, and bladder. According to the U.S. National Cancer Institute source cited in the original announcement, carcinomas account for 80% to 90% of all cancers.
Enrichment of CTCs of epithelial origin is increasingly a focus of liquid biopsy research and development.
Using Cellular and Cell-Free Fractions Together
The Revolution CTC Enrichment Kit (Epithelial Cell Origin) is nRichDX's latest application for its Revolution Sample Prep System™ platform.
Data using the new CTC enrichment kit as a complement to nRichDX's existing cfTNA kit were presented at the Cancer Genomics Consortium (CGC) 2023 Annual Meeting in a poster titled, Extraction of Multiple Analytes in Liquid Biopsy May Improve the Diagnosis of Breast Cancer .
The research demonstrated utilization of a blood sample's cellular and non-cellular plasma fractions to provide more liquid biopsy analytes and a more comprehensive assessment of cancer markers that may be present in the blood.
Developed with University Medical Center Hamburg-Eppendorf
The new nRichDX Revolution CTC Enrichment Kit (Epithelial Cell Origin) was developed in collaboration with the liquid biopsy research laboratory at University Medical Center Hamburg-Eppendorf (UKE), led by Dr. Klaus Pantel in Hamburg, Germany.
“nRichDX's ongoing mission is the development of better tools and applications for Researchers and Clinicians revolutionizing cancer diagnosis through liquid biopsy.”
“We're excited to introduce the first of a new line of better CTC enrichment tools to advance liquid biopsy development and implementation,” Curtis said.
Immunomagnetic Enrichment Using EpCAM
The Revolution CTC Enrichment Kit (Epithelial Cell Origin) utilizes immunomagnetic enrichment with antibodies to established cellular markers, including Epithelial Cell Adhesion Molecule (EpCAM).
The kit is optimized to isolate greater numbers of CTCs and fewer non-relevant artifacts.
At the time of the announcement, nRichDX also stated that future CTC enrichment kits would focus on additional CTC cancer markers specific to other cancer types.
Explore the CTC Enrichment KitAbout nRichDX
nRichDX® is an emerging leader in sample prep solutions for isolating cfDNA, cfRNA, and enrichment of CTCs. The patented Revolution Sample Prep System™ was engineered specifically for liquid biopsy applications.
It is the first and only high-yield, high-recovery, IVD-labeled sample prep platform that can process from 1 mL to 20 mL of plasma or urine sample volumes or up to 40 mL of blood in a single extraction using the company's unique nRicher Cartridge™.
Unlike other methods, Revolution sample prep doesn't require yield-lowering eluate pooling or sample transfer steps. nRichDX helps solve one of precision medicine's greatest problems: inaccurate or incomplete diagnostic results for liquid biopsy-based applications due to insufficient analyte.
Learn more about nRichDXCarcinoma Classification
i NIH, National Cancer Institute, Cancer Classification, SEER Training Modules. Accessed August 4, 2023.
View NCI Reference